The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2025

Filed:

Aug. 23, 2022
Applicants:

Gracell Biotechnologies (Shanghai) Co., Ltd., Shanghai, CN;

Suzhou Gracell Biotechnologies Co., Ltd., Jiangsu, CN;

Inventors:

Xinxin Wang, Shanghai, CN;

Tao Jin, Shanghai, CN;

Chunhui Yang, Shanghai, CN;

Zhongdong Shi, Shanghai, CN;

Liping Liu, Shanghai, CN;

Jing Sun, Shanghai, CN;

Shuyi Qiu, Shanghai, CN;

Wei Cao, Shanghai, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 40/50 (2025.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01); A61K 35/38 (2015.01); A61K 35/545 (2015.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 40/4204 (2025.01); A61K 40/421 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); A61P 35/00 (2018.01); C07K 14/70507 (2013.01); C07K 14/70596 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 40/50 (2025.01); A61K 2239/23 (2023.05); A61K 2239/29 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05);
Abstract

The present disclosure relates to an engineered immune cell and use thereof. The present disclosure provides an engineered immune cell comprising a CAR or engineered TCR, which CAR or engineered TCR can comprise a first antigen binding domain and a second antigen binding domain. The engineered immune cells of the present disclosure, when administered into a subject, can inhibit the host immune cells such as T cells and/or NK cells and enhance the survival and persistence of the engineered immune cells in vivo, thereby exhibiting more effective tumor killing activity.


Find Patent Forward Citations

Loading…